Etoricoxib in the treatment of active sacroiliitis in patients with axial spondyloarthritis, including ankylosing spondylitis


Cite item

Full Text

Abstract

AIM. To study a trend in active sacroiliitis (ASI) in patients with axial spondyloarthritis (axSpA) during different short-term regimens using etoricoxib (ET) 90 mg. MATERIALS AND METHODS. Forty patients with axSpA, including 30 with ankylosing spondyloarthritis), and ASI (sacroiliac joint (SIJ) osteitis as evidenced by magnetic resonance imaging) were examined and then randomized to 2 groups: 1) 20 patients who took ET 90 mg four days or more a week; 2) 20 patients who received ET 90 mg 3 days or less a week. Osteitis was measured in 4 quadrants of each SIJ (0-3 scores). Its main criterion was considered to be a decrease in total osteitis activity (TOA) 12 week later. RESULTS. In all the patients (n=40), TOA decreased from 6.5 (4; 9) to 2 (0; 5) scores (p<0.0001). In Group 1 (n=20), that reduced from 6.5 (4; 8.5) to 0 (0; 3) scores (p<0.0001). In Group 2 (n=20), that did from 6.5 (4; 10) to 4 (1; 8) scores (p=0.49). At 12 weeks, in in Groups 1 and 2, the difference in final TOA achieved no statistical significance (p=0.056). In these groups, there were 19 (95%) and 14 (70%) treatment-responsive patients, respectively. Conclusion. The intake of ET 90 mg for 12-weeks is associated with a reduction in the degree of ASI in patients with axSpA. The use of ET 4 times or more a week is more effective in diminishing osteitis than that of ET 3 days or less.

Full Text

Эторикоксиб в лечении активного сакроилеита у больных аксиальными спондилоартритами, включая анкилозирующий спондилит. - Резюме. Цель исследования. Изучение динамики активного сакроилеита (АСИ) у пациентов с аксиальными спондилоартритами (аксСпА) при различных режимах назначения эторикоксиба (ЭТ) в дозе 90 мг в краткосрочной перспективе. Материалы и методы. Обследовали 40 пациентов с аксСпА (из них 30 с анкилозирующим спондилитом), имеющих АСИ (остеит крестцово-подвздошные сочленения - КПС по данным магнитно-резонансной томографии), после чего рандомизировали на 2 группы: 1-я - 20 пациентов, которые принимали ЭТ в дозе 90 мг 4 дня в неделю и более, 2-я - 20 пациентов, которые принимали ЭТ в дозе 90 мг в режиме 3 дня в неделю и менее. Для каждого КПС оценивали остеит (ОТ) в 4 квадрантах (0-3 балла). Основным критерием считали уменьшение суммарной оценки активности остеита (СОАО) через12 нед. Результаты. У всех 40 пациентов СОАО уменьшился с 6,5 (4; 9) до 2 (0; 5) баллов (p<0,0001). У 20 пациентов 1-й группы СОАО уменьшился с 6,5 (4; 8,5) до 0 (0; 3) баллов (p<0,0001). У 20 пациентов 2-й группы СОАО уменьшился с 6,5 (4; 10) до 4 (1;8) баллов (p=0,49). К 12-й неделе различия итогового СОАО у пациентов 1-й и 2-й групп не достигло статистической значимости (p=0,056). В 1-й группе число ответивших на лечение составило 19 (95%), во 2-й группе - 14 (70%). Заключение. Прием ЭТ в дозе 90 мг в течение 12 нед ассоциируется с уменьшением выраженности АСИ у пациентов с аксСпА. Прием ЭТ 4 раза в неделю и более эффективнее в уменьшении ОТ, чем в режиме 3 дня в неделю и менее.
×

References

  1. Каратеев А.Е. Нестероидные противовоспалительные препараты в современной клинической практике: "за" больше, чем "против". Совр ревматол 2008; 1: 70-77.
  2. Poddubnyy D., van der Heijde D. Therapeutic controversies in spondyloarthritis: nonsteroidal anti-inflammatory drugs. Rheum Dis Clin North Am 2012; 38 (3): 601-611.
  3. Braun J., van den Berg R., Baraliakos X. et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70 (6): 896-904.
  4. Wanders A., van der Heijde D., Landewe R. et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005; 52: 1756-1765.
  5. Poddubnyy D., Rudwaleit M., Haibel H. et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 2012; 71 (10): 1616-1622.
  6. Poddubnyy D., Haibel H., Listing J. et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum 2012; 64 (5): 1388-1398.
  7. Patrignani P., Capone M.L., Tacconelli S. Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. Expert Opin Pharmacother 2003; 4 (2): 265-284.
  8. Machado P., Landewé R.B., Braun J. et al. MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor. Ann Rheum Dis 2012; 71 (12): 2002-2005.
  9. Dougados M., van der Heijde D., Sieper J. et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 2014; 66 (8): 2091-2102.
  10. Goh L., Suresh P., Gafoor A. et al. Disease activity in longstanding ankylosing spondylitis: a correlation of clinical and magnetic resonance imaging findings. Clin Rheumatol 2008; 27 (4): 449-455.
  11. Rudwaleit M., Schwarzlose S., Hilgert E.S. et al. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 2008; 67 (9): 1276-1281.
  12. atients with ankylosing spondylitis eligible for anti-tumour Lories R.J. Etoricoxib and the treatment of ankylosing spondylitis. Expert Opin Drug Metab Toxicol 2012; 8 (12): 1599-1608.
  13. Jarrett S.J., Sivera F., Cawkwell L.S. et al. MRI and clinical findings in p necrosis factor therapy after a short course of etoricoxib. Ann Rheum Dis 2009; 68 (9): 1466-1469.
  14. Rudwaleit M., Landewe R., van der Heijde D. et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 2009; 68 (6): 770-776.
  15. Bennett P.H., Burch T.A. Population studies of the rheumatic diseases. Amsterdam: Excerpta Medica Foundation International Congress Series 148. 1966: 456-457.
  16. van der Linden S., Valkenburg H.A., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27 (4): 361-368.
  17. Rudwaleit M., Jurik A.G., Hermann K.G. et al. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis 2009; 68 (10): 1520-1527.
  18. Garrett S., Jenkinson T., Kennedy L. et al. New approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286-2222.
  19. Lukas C., Landewe R., Sieper J. et al; Assessment of SpondyloArthritis international Society. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68 (1): 18-24.
  20. Laine L., Curtis S.P., Cryer B. et al.; MEDAL Steering Committee. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac. Arthritis Long-term (MEDAL) programme: a randomized comparison. Lancet 2007; 369: 465-473.
  21. Hunt R.H., Harper S., Watson D.J. et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003; 98 (8): 1725-1733.
  22. Martina S.D., Vesta K.S., Ripley T.L. Etoricoxib: a highly selective COX-2 inhibitor. Ann Pharmacother 2005; 39 (5): 854-862.
  23. Van der Heijde D., Baraf H.S., Ramos-Remus C. et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005; 52: 1205-1215.
  24. Poddubnyy D., Gaydukova I., Hermann K.G. et al. Performance of magnetic resonance imaging for the detection of chronic structural changes in the sacroiliac joints as compared to conventional x-rays in axial spondyloarthritis. J Rheumatol 2013; 40 (9): 1557-1565.
  25. Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. М: Медиа-Сфера 2002.
  26. Amor B., Dougados M., Khan M.A. Management of refractory ankylosing spondylitis and related spondyloarthropathies. Rheum Dis Clin North Am 1995; 21 (1): 117-128.
  27. Maquirriain J., Kokalj A. Management of acute Achilles tendinopathy: effect of etoricoxib on pain control and leg stiffness. Georgian Med News 2013; 222: 36-43.
  28. Poddubnyy D., Rudwaleit M., Haibel H. et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70 (8): 1369-1374.
  29. Maksymowych W.P., Wichuk S., Chiowchanwisawakit P. et al. Fat metaplasia and backfill are key intermediaries in the development of sacroiliac joint ankylosis in patients with ankylosing spondylitis. Arthritis Rheumat 2014. doi: 10.1002/art.38792. [Epub ahead of print].
  30. Baraliakos X., Haibel H., Listing J. et al. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis 2014; 73(4): 710-715.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies